# A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

> **NCT02195479** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 706 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Melphalan
- **DRUG:** Prednisone
- **DRUG:** Daratumumab IV
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab SC

## Key facts

- **NCT ID:** NCT02195479
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2017-11-21
- **Final completion:** 2024-08-07
- **Target enrollment:** 706 (ACTUAL)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02195479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02195479, "A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02195479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*